Financials data is unavailable for this security.
View more
Year on year Jiangsu Cowin Biotech Co Ltd 's revenues fell -67.15% from 521.60m to 171.34m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 159.26m to a loss of 84.41m.
| Gross margin | 53.54% |
|---|---|
| Net profit margin | -126.60% |
| Operating margin | -151.86% |
| Return on assets | -8.45% |
|---|---|
| Return on equity | -8.93% |
| Return on investment | -8.93% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Jiangsu Cowin Biotech Co Ltd fell by 684.29m. In addition, the company used more cash to support its operations than it earned, posting a cash flow loss of 11.72m. In addition the company used 620.91m on investing activities and also paid 52.30m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 13.63 |
|---|---|
| Tangible book value per share | 13.36 |
More ▼
Balance sheet in CNYView more
| Current ratio | 14.26 |
|---|---|
| Quick ratio | 13.60 |
| Total debt/total equity | 0.0221 |
|---|---|
| Total debt/total capital | 0.0214 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -100.00% and -141.97%, respectively.
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -455.47 |
